全球液体活检市场规模、份额、成长分析，按类型（试剂和试剂盒和仪器）、最终用户（医院、诊所和研究中心）- 2024-2031 年行业预测

Global Liquid Biopsy Market Size, Share, Growth Analysis, By Type(Reagents and Kits, and Instruments), By End-User(Hospitals and Clinics, and Research Centres) - Industry Forecast 2024-2031

出版日期: 2024年04月09日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球液体切片市场规模为94亿美元，预计将从2023年的106.9亿美元成长到2031年的298.5亿美元，在预测期间（2024-2031年）复合年增长率为13.7%。

市场扩张的主要驱动力是癌症发生率的上升以及对微创诊断程序的需求急剧增加。在美国，非小细胞肺癌是最常见的疾病类型。一项分析显示，到 2021 年，将有超过 235,760 人被诊断出非小细胞肺癌。作为一般人群诊断和治疗癌症的一种手段，液体活检的需求越来越大。企业提供简单、安全的家庭访问的方法也推动了市场的扩张。例如，资讯服务供应商 NeoGenomics, Inc. 于 2020 年 11 月宣布推出 NeoLAB 和 InvisionFirst，这是一项液体活检测试行动静脉切开术服务。该组织透过 ExamOne 和 Metro Health Staffing LLC 提供服务，以确保考试的有效管理。透过提供传统筛检的有效替代品，液体活检致力于促进早期癌症检测和疾病预防。他们的天性真的很敏感。血液检查结果提供有关病情严重程度和建议治疗方案的资讯。因此，製药和生物技术行业研发活动的增加以及政府对各种研究项目的资助增加刺激了市场的扩张。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 欧洲其他地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 拉丁美洲其他地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- MEA 的其余部分

竞争格局

前 5 名玩家比较
2021 年关键参与者的市场定位
主要市场参与者所采取的策略
最佳制胜策略
近期市集活动
主要公司市占率（%），2021年

主要公司简介

F. Hoffmann-La Roche Ltd (Switzerland)
Thermo Fisher Scientific Inc. (US)
QIAGEN NV (Netherlands)
Illumina, Inc. (US)
Guardant Health, Inc. (US)
Biocept, Inc. (US)
Sysmex Corporation (Japan)
Menarini Silicon Biosystems (Italy)
Natera, Inc. (US)
GRAIL, Inc. (US)
Biocartis Group NV (Belgium)
Personal Genome Diagnostics Inc. (US)
Exosome Diagnostics, Inc. (US)
Bio-Rad Laboratories, Inc. (US)
Genomic Health, Inc. (US)
RainDance Technologies, Inc. (US)
OncoCyte Corporation (US)
Adaptive Biotechnologies Corporation (US)
Angle plc (United Kingdom)
Epic Sciences, Inc. (US)

简介目录

Product Code: SQMIG35J2060

Global Liquid Biopsy Market size was valued at USD 9.4 billion in 2022 and is poised to grow from USD 10.69 billion in 2023 to USD 29.85 billion by 2031, growing at a CAGR of 13.7% during the forecast period (2024-2031).

The primary drivers of the market's expansion are the rising incidence of cancer and the sharp rise in demand for less invasive diagnostic procedures. In the United States, non-small cell lung cancer is the most prevalent type of the disease. An analysis revealed that in 2021, over 235,760 persons will receive a non-small cell lung cancer diagnosis. Liquid biopsy tests are in greater demand as a means of diagnosing and curing cancer in the general population. The approach taken by businesses to provide simple and secure in-home access also propels the market's expansion. For example, the information services provider NeoGenomics, Inc. announced the launch of NeoLAB and InvisionFirst in November 2020.It is a liquid biopsy testing mobile phlebotomy service. The organization provides its services via ExamOne and Metro Health Staffing LLC to guarantee that exams are administered effectively. By providing an effective substitute for conventional screening, liquid biopsy seeks to promote early cancer detection and disease prevention. Their nature is really sensitive. The blood test results provide information about the severity of the condition and the recommended course of treatment. Therefore, the expansion of the market is stimulated by an increase in R&D activities in the pharmaceutical and biotechnology industries as well as an increase in government funding for various research projects.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liquid Biopsy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liquid Biopsy Market Segmental Analysis

The Global Liquid Biopsy market is segmented by type, end-user, and region. Based on type, the market can be segmented into reagents and kits, and instruments. Based on end-user, the market is segmented into hospitals and clinics segment, and research centres. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Liquid Biopsy Market

The need for early detection and the rising incidence of cancer are two main factors propelling the worldwide liquid biopsy market's expansion. Early cancer diagnosis and treatment are time-consuming, intrusive procedures that can make patients uncomfortable. Furthermore, the industry is growing thanks to the application of cutting-edge liquid biopsy testing for cancer diagnosis. A less intrusive and uncomfortable method for cancer monitoring and diagnosis is the liquid biopsy. Additionally, the liquid biopsy test aids in the early detection of cancer. As a result, these elements stimulate market expansion and raise demand for liquid biopsy tests.

Restraints in the Global Liquid Biopsy Market

The absence of standardization and regulatory norms for liquid biopsy tests impedes the market's expansion. Liquid biopsy test approval is a complex and time-consuming process regulated by regulations. The introduction of new products onto the market is further delayed by this. The market's expansion is further hampered by the expensive nature of liquid biopsy testing and the narrow coverage of reimbursements. These difficulties may be addressed with the introduction of defined criteria and expanded reimbursement coverage for liquid biopsy tests.

Market Trends of the Global Liquid Biopsy Market

One of the major developments in the global liquid biopsy market is the growing use of next-generation sequencing technology. RNA and DNA molecules may be sequenced at high throughput with the NGS, making it possible to identify cancer biomarkers from a single sample. This technique is mostly utilized in liquid biopsy procedures with the goal of delivering extremely sensitive and specific data for cancer monitoring and early diagnosis. As a result, the market is expanding due to the spike in demand for NGS liquid biopsy tests.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Liquid Biopsy Market by Type

Market Overview
Reagents and Kits
and Instruments

Global Liquid Biopsy Market by End-User

Market Overview
Hospitals and Clinics
and Research Centres

Global Liquid Biopsy Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocept, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Menarini Silicon Biosystems (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GRAIL, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocartis Group NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Personal Genome Diagnostics Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exosome Diagnostics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genomic Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RainDance Technologies, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OncoCyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adaptive Biotechnologies Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Angle plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Epic Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments